Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chemomab Therapeutics Ltd ADR
(NQ:
CMMB
)
1.220
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
57,135
Open
1.190
Bid (Size)
1.260 (31)
Ask (Size)
1.280 (18)
Prev. Close
1.220
Today's Range
1.190 - 1.220
52wk Range
0.4200 - 1.580
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
August 21, 2024
Chemomab Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 21, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Performance
YTD
+126.85%
+126.85%
1 Month
+5.17%
+5.17%
3 Month
+45.24%
+45.24%
6 Month
+80.47%
+80.47%
1 Year
+9.91%
+9.91%
More News
Read More
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
August 12, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
July 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
July 26, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
July 25, 2024
Via
Benzinga
Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
June 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
June 06, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 17, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
May 09, 2024
Via
InvestorPlace
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 08, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
May 06, 2024
Via
Benzinga
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
May 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
March 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
March 07, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 22, 2024
Via
Benzinga
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 20, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.